| Name | Title | Contact Details |
|---|---|---|
Yamel Gonzalez |
Chief Information Officer | Profile |
Based in North Carolina, the partnership of UNX and Christeyns brings together more than 100 years of experience in the textile care industry. Specializing in commercial quality cleaning chemicals for the laundry, housekeeping, warewashing, and dry and wet cleaning markets, these products are supported with custom designed dispensing equipment to produce high efficiency results for customers. Learn more by calling 800-869-6171 for more information or by visiting our website.
Geofabrica is a manufacturing technology development company specializing in customized additive manufacturing systems for factory and expeditionary applications. We build innovative solutions to unlock the economic and production potential of 3D printing and additive technologies for metal, plastic, and composite applications. We create application-specific devices and processes to help customers overcome the limitations of current technologies and help them achieve a competitive advantage within the evolving digital manufacturing landscape. ITAR registered, JCP certified, NIST 800-171 compliant.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
PremiumIQ helps insurance companies increase premiums, reduce losses and engage customers with advanced data solutions. We assist data analytics teams in achieving faster results, fostering trust, and effectively managing costs. Were data specialists focused singularly on helping insurance clients implement next generation applications, architectures, and operating models.